title: Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults.
abstract: BACKGROUND
  MAS063DP (Atopiclair) is a topical cream approved for symptomatic relief in the treatment of atopic and contact dermatitis.
  
  
  METHODS
  This was a multicenter, randomized, double-blind, vehicle-controlled study in adults with mild-moderate atopic dermatitis. Patients were given MAS063DP or vehicle (2:1) three times per day to areas affected by atopic dermatitis for up to 50 days. A patient global assessment change from baseline was determined at days 8, 22, 36, and 50. Patient total body pruritus (visual analog scale) and patient opinion on treatment acceptability were also assessed.
  
  
  RESULTS
  A total of 218 patients (active: n = 145, vehicle: n = 73) were enrolled. At Day 22, 77% of patients on MAS063DP had a patient global assessment of good improvement or better versus 21% on vehicle (p<0.0001, chi-squared test). Similarly, more patients had improvement in itch over their total body on MAS063DP than on vehicle (p<0.0001).
  
  
  CONCLUSIONS
  MAS063DP treatment results in patient-perceived improvements in mild-moderate atopic dermatitis.
authors: Department of Dermatology, Baylor University Medical Center and University of Texas Southwestern School of Medicine, Dallas, TX, USA. DrA@DermCenter.us
authors: William
authors: W
authors: Abramovits
authors: Adelaide A
authors: AA
authors: Hebert
authors: Mark
authors: M
authors: Boguniewicz
authors: Steven E
authors: SE
authors: Kempers
authors: Eduardo
authors: E
authors: Tschen
authors: Michael T
authors: MT
authors: Jarratt
authors: Anne W
authors: AW
authors: Lucky
authors: Raymond L
authors: RL
authors: Cornelison
authors: Leonard J
authors: LJ
authors: Swinyer
authors: Terry M
authors: TM
authors: Jones
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004041:Dietary Fats / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010936:Plant Extracts / Q000008:administration & dosage*; D012720:Severity of Illness Index; D013781:Texas; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D004041:Dietary Fats; C530270:MAS063DP; D009824:Ointments; D010936:Plant Extracts; D006034:Glycyrrhetinic Acid